The equine tendon medication Bapten has been discontinued by its manufacturer, PR Pharmaceuticals, because of a lack of demand for the product. The expense and length of treatment involved with Bapten therapy kept the drug from becoming popular with horse owners, according to Keri Nightingale, the company's marketing manager for Bapten.
"It requires a bit of a commitment on the horse
To continue reading this article, become a member of TheHorse.com.
It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.













